VITA 34 Valuation
Is 0NLV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0NLV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0NLV (€4.19) is trading below our estimate of fair value (€10.22)
Significantly Below Fair Value: 0NLV is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0NLV?
Key metric: As 0NLV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0NLV's PS Ratio? | |
|---|---|
| PS Ratio | 0.9x |
| Sales | €78.82m |
| Market Cap | €73.91m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | 19.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0NLV's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.3x | ||
KOO Kooth | 1.1x | 9.4% | UK£60.4m |
IDHC Integrated Diagnostics Holdings | 2.3x | 19.1% | US$225.8m |
CUSH CRUSHMETRIC Group | 42.8x | n/a | UK£30.0m |
GENI GENinCode | 2.8x | n/a | UK£7.3m |
0NLV VITA 34 | 0.9x | 3.1% | €73.9m |
Price-To-Sales vs Peers: 0NLV is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (12.3x).
Price to Sales Ratio vs Industry
How does 0NLV's PS Ratio compare vs other companies in the European Healthcare Industry?
| 7 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 7 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 0NLV is expensive based on its Price-To-Sales Ratio (0.9x) compared to the European Healthcare industry average (0.6x).
Price to Sales Ratio vs Fair Ratio
What is 0NLV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0NLV's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Arjo
SEK 9.2b
Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.
0HQ8
SEK 33.92
7D
-4.8%
1Y
-9.6%
Guerbet
€339.2m
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
0ELV
€27.00
7D
-9.8%
1Y
50.2%
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
0HNZ
€18.06
7D
-6.1%
1Y
5.3%